Abstract: Methods of preventing and treating gastrointestinal dysfunction, particularly postoperative ileus and post-partum ileus, in a patient undergoing surgery or other biological stress by administering 4-aryl-piperidine derivatives are disclosed.
Type:
Grant
Filed:
November 29, 2004
Date of Patent:
February 3, 2015
Assignee:
Adolor Corporation
Inventors:
David D Christ, Bruce A Wallin, Deanne D Garver, William K Schmidt, David Jackson
Abstract: Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.
Type:
Grant
Filed:
March 10, 2014
Date of Patent:
November 25, 2014
Assignee:
Adolor Corporation
Inventors:
Roland E. Dolle, Bertrand Le Bourdonnec, Allan James Goodman
Abstract: Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.
Type:
Application
Filed:
March 10, 2014
Publication date:
July 3, 2014
Applicant:
Adolor Corporation
Inventors:
Roland E. Dolle, Bertrand Le Bourdonnec, Allan James Goodman
Abstract: Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection. The results are achieved by a combination of processing techniques and component selection.
Abstract: Novel methods for delivering a drug to hospital patients for short-term in-hospital use while minimizing long-term use of the drug. Embodiments are provided in which hospitals are identified which may be eligible to treat patients, for example, perform certain types of surgery, and which have measures in place to limit use of the drug to short-term use. The identified hospitals are preferably registered in a storage medium, including computer readable storage media, and may be authorized to receive the shipments of the drug. The received drug may then be dispensed to the patient.
Type:
Application
Filed:
October 18, 2013
Publication date:
February 13, 2014
Applicant:
Adolor Corporation
Inventors:
George Raymond MAURER, Robert Barnett JONES
Abstract: Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection. The results are achieved by a combination of processing techniques and component selection.
Abstract: Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.
Type:
Application
Filed:
July 25, 2013
Publication date:
November 28, 2013
Applicant:
Adolor Corporation
Inventors:
Roland E. Dolle, Bertrand Le Bourdonnec, Allan James Goodman
Abstract: Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.
Type:
Grant
Filed:
May 24, 2012
Date of Patent:
November 12, 2013
Assignee:
Adolor Corporation
Inventors:
Roland E. Dolle, Bertrand Le Bourdonnec, Allan James Goodman
Abstract: 3,4-Disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.
Type:
Grant
Filed:
January 17, 2011
Date of Patent:
March 26, 2013
Assignee:
Adolor Corporation
Inventors:
Roland E. Dolle, Bertrand Le Bourdonnec
Abstract: Novel methods for delivering a drug to hospital patients for short-term in-hospital use while minimizing long-term use of the drug. Embodiments are provided in which hospitals are identified which may be eligible to treat patients, for example, perform certain types of surgery, and which have measures in place to limit use of the drug to short-term use. The identified hospitals are preferably registered in a storage medium, including computer readable storage media, and may be authorized to receive the shipments of the drug. The received drug may then be dispensed to the patient.
Type:
Application
Filed:
July 3, 2012
Publication date:
January 3, 2013
Applicant:
Adolor Corporation
Inventors:
George Raymond MAURER, Robert Barnett JONES
Abstract: Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.
Type:
Grant
Filed:
October 5, 2010
Date of Patent:
October 16, 2012
Assignee:
Adolor Corporation
Inventors:
Bertrand Le Bourdonnec, Roland E. Dolle
Abstract: Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.
Type:
Grant
Filed:
May 11, 2009
Date of Patent:
October 2, 2012
Assignee:
Adolor Corporation
Inventors:
Roland E. Dolle, Bertrand Le Bourdonnec, Allan James Goodman
Abstract: Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.
Type:
Application
Filed:
May 24, 2012
Publication date:
September 13, 2012
Applicant:
Adolor Corporation
Inventors:
Roland E. Dolle, Bertrand Le Bourdonnec, Allan James Goodman
Abstract: Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection. The results are achieved by a combination of processing techniques and component selection.
Abstract: This present disclosure provides compositions comprising E-10-OH-NT metabolites of AT and NT, methods for their synthesis and methods for their use.
Type:
Application
Filed:
March 22, 2012
Publication date:
July 12, 2012
Applicant:
Adolor Corporation
Inventors:
Bertrand LE BOURDONNEC, Roland E. Dolle
Abstract: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the ? opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other ? opioid receptor-mediated conditions.
Type:
Application
Filed:
October 17, 2011
Publication date:
June 28, 2012
Applicant:
Adolor Corporation
Inventors:
Roland E. Dolle, Bertrand Le Bourdonnec
Abstract: Novel methods for delivering a drug to hospital patients for short-term in-hospital use while minimizing long-term use of the drug. Embodiments are provided in which hospitals are identified which may be eligible to treat patients, for example, perform certain types of surgery, and which have measures in place to limit use of the drug to short-term use. The identified hospitals are preferably registered in a storage medium, including computer readable storage media, and may be authorized to receive the shipments of the drug. The received drug may then be dispensed to the patient.
Type:
Application
Filed:
December 29, 2011
Publication date:
April 26, 2012
Applicant:
Adolor Corporation
Inventors:
George Raymond Maurer, Robert Barnett Jones
Abstract: Novel methods for delivering a drug to hospital patients for short-term in-hospital use while minimizing long-term use of the drug. Embodiments are provided in which hospitals are identified which may be eligible to treat patients, for example, perform certain types of surgery, and which have measures in place to limit use of the drug to short-term use. The identified hospitals are preferably registered in a storage medium, including computer readable storage media, and may be authorized to receive the shipments of the drug. The received drug may then be dispensed to the patient.
Type:
Grant
Filed:
May 15, 2009
Date of Patent:
February 7, 2012
Assignee:
Adolor Corporation
Inventors:
George Raymond Maurer, Robert Barnett Jones
Abstract: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the ? opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other ? opioid receptor-mediated conditions.
Type:
Grant
Filed:
March 5, 2010
Date of Patent:
December 6, 2011
Assignee:
Adolor Corporation
Inventors:
Roland E. Dolle, Bertrand Le Bourdonnec